Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
1. Alpha Tau's IMPACT trial for pancreatic cancer has begun patient treatment. 2. Study evaluates Alpha DaRT with chemotherapy for inoperable pancreatic cancer. 3. Pancreatic cancer has high inoperability and poor treatment outcomes. 4. CEO emphasizes urgent need for innovative treatments in this patient population. 5. Trial aims for high-quality data on safety and efficacy for future directions.